TET inhibitors are small molecules that suppress the activity of Ten-Eleven Translocation (TET) dioxygenases (TET1, TET2, and TET3), key enzymes responsible for DNA demethylation through the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and subsequent intermediates. Because TET proteins play essential roles in epigenetic regulation, stem cell biology, and cellular differentiation, abnormal TET activity has been associated with acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), breast and lung cancers, neurodegenerative disorders, and inflammatory diseases. Consequently, TET inhibition has emerged as a promising strategy for epigenetic research and the development of targeted cancer and immunotherapy approaches.

Key TET Inhibitors and Their Mechanisms

• TETi76: An orally bioavailable pan-TET inhibitor with potent activity against TET1, TET2, and TET3. It decreases genomic hydroxymethylation and suppresses the growth of TET2-mutant cells, making it valuable for leukemia research.
• Bobcat339: A selective cytosine-based inhibitor that preferentially targets TET1 and TET2. It inhibits IL-1β-induced DNA demethylation and epithelial-mesenchymal transition (EMT) while exhibiting limited effects on TNFα-mediated signaling.
• NSC-370284: An indirect TET inhibitor that suppresses STAT3/STAT5 signaling, resulting in reduced TET1 expression and lower cellular 5hmC levels, particularly in acute myeloid leukemia models.
• 2-Hydroxyglutarate (2HG): An oncometabolite that inhibits TET enzyme activity, with TET2 and TET3 showing greater sensitivity than TET1. This differential inhibition may contribute to the mutation patterns observed in AML.

Research Applications

TET inhibitors are widely used as chemical probes to investigate DNA methylation dynamics, epigenetic regulation, and disease-associated signaling pathways. Bobcat339 has been instrumental in distinguishing IL-1β-dependent from TNFα-dependent inflammatory responses in osteosarcoma models. In parallel, next-generation bisubstrate inhibitors that combine substrate and cofactor analogues have demonstrated enhanced selectivity toward TET2, while prodrug approaches improve intracellular delivery. Additional inhibitor classes, including 8-hydroxyquinoline derivatives, continue to expand the toolkit available for studying TET biology and developing novel epigenetic therapeutics.